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Introduction: melatonin (MT) is a hormone produced by the pineal gland at night, involved in the
regulation of circadian rhythms. For clinical purposes, exogenous MT administration should mimic
the typical nocturnal endogenous MT levels, but its pharmacokinetics is not favourable due to short
half-life of elimination. Aim of this study is to examine pharmacokinetics of MT incorporated in solid
lipid nanoparticles (SLN), administered by oral and transdermal route. SLN peculiarity consists in
the possibility of acting as a reservoir, permitting a constant and prolonged release of the drugs
included. In 7 healthy subjects SLN incorporating MT 3 mg (MT-SLN-O) were orally administered at
8.30 a.m. MT 3 mg in standard formulation (MT-S) was then administered to the same subjects after
one week at 8.30 a.m. as controls. In 10 healthy subjects SLN incorporating MT were administered
transdermally (MT-SLN-TD) by the application of a patch at 8.30 a.m. for 24 hours. Compared to
MT-S, Tmax after MT-SLN-O administration resulted delayed of about 20 minutes, while mean AUC
and mean half life of elimination was significantly higher (respectively 169944.7±64954.4 pg/ml ×
hour vs. 85148.4± 50642.6 pg/ml × hour, p = 0018 and 93.1± 37.1 min vs. 48.2± 8.9 min,
p = 0009). MT absorption and elimination after MT-SLN-TD demonstrated to be slow (mean half
life of absorption: 5.3±1.3 hours; mean half life of elimination: 24.6±12.0 hours), so MT plasma
levels above 50 pg/ml were maintained for at least 24 hours. This study demonstrates a significant
absorption of MT incorporated in SLN, with detectable plasma level achieved for several hours in
particular after transdermal administration. As dosages and concentrations of drugs included in
SLN can be varied, different plasma level profile could be obtained, so disclosing new possibilities
for sustained delivery systems.
Keywords: Solid Lipid Nanoparticles, Melatonin, Transdermal.
1. INTRODUCTION
Melatonin (N -acetyl-5methoxytryptamine, MT) is a hor-
mone produced by the pineal gland at night. It is involved
in the regulation of sleep and circadian rhythms, work-
ing as a time-of-day information to various organs.12 The
synthesis and secretion of MT is induced by darkness and
suppressed by light through retinal nerve fibers project-
ing to the suprachiasmatic nucleus of hypothalamus, then
to the superior cervical ganglion and finally to the pineal
∗Author to whom correspondence should be addressed.
gland.3 Plasma MT levels are low during the day, about
10 pg/ml in young adults, with a pulse of secretion start-
ing at 9 p.m. and reaching a peak of about 70–100 pg/ml
between 2 and 4 a.m. Plasma MT levels then return to
baseline at 7–9 a.m.4 With aging and in healthy individu-
als with insomnia nocturnal peak level of MT is reported
to be lower and delayed of about one hour compared to
young adults with good sleep quality.56 MT has proved to
be useful particularly in disorders of sleep-wake cycle and
in insomnia of the elderly.7 Nevertheless, no doses or exact
timing of administration have yet been agreed for any con-
dition, due to inconstancy of clinical results, variability
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of pharmacokinetic studies and lack of data comparing
the efficacy of various formulations. For clinical purposes,
exogenous MT administration should be able to mimic the
typical nocturnal endogenous MT levels, but its pharma-
cokinetics is not favourable. After an intravenous bolus
injection MT half-life of elimination is very short (about
40 min)8 and, when administer orally, MT shows low
bioavailability and a rapid clearance from plasma influ-
enced by a marked firs pass hepatic metabolism.9 Over
80% of MT is then excreted in the urine as 6-SMT. There-
fore MT is not a good candidate for conventional oral
immediate release system and a sustained release delivery
system is required in order to maintain prolonged plasma
MT concentrations. Transdermal delivery systems of MT
have been described by several authors.10–12 They should
have the advantage of avoiding first-pass metabolism but
may not be practical for particular purposes.
Aim of this study is to examine in voluntary healthy
subjects the release and pharmacokinetics of MT incor-
porated in solid lipid nanoparticles (SLN), administered
orally and by transdermal route, after dispersion in an
expressly-studied vehicle. The peculiarity of these two
new formulations is the use of SLN prepared from warm
microemulsions. SLN can incorporate hydrophilic and lipo-
philic drugs, work as a reservoir for sustained release of
them and are targeted to lymph after duodenal administra-
tion.13–15 Moreover stealth-SLN can be prepared to avoid
their recognition by reticuloendothelial system.1617 SLN
have been successfully administered to laboratory animals
via duodenal,15 parenteral,18 and ocular routes.19 MT incor-
porated in SLN (MT-SLN) has been chosen for our in vivo
study because of the safeness of MT administration in
humans even at high dosages.7 Our study intends to furnish
a general model for sustained release delivery systems of
drugs devoid of favourable pharmacokinetics and requiring
therapeutic plasma levels lasting for several hours.
2. MATERIALS AND METHODS
2.1. MT Incorporated in SLN (MT-SLN)
2.1.1. Components
Melatonin was a kind gift by Helsinn (Biasca, Switzer-
land), stearic acid was from Merck, Epikuron 200 (Soya
phosphatidylcholine 95%) was a kind gift from Degussa
(Hamburg, Germany), taurocholate sodium salt was a kind
gift from PCA (Basaluzzo, Italy). The other chemicals
were of analytical grade.
2.1.2. Preparation of SLN
Melatonin was added to a mixture of stearic acid and
Epikuron 200, melted at about 70 C. Successively a
solution of sodium taurocholate in water, heated at the
same temperature, was added. Using the right amounts
of the components clear warm microemulsions were
achieved. SLN were then obtained by dispersing the
warm microemulsion in cold water (2–3). The dispersion
was successively washed three times by ultrafiltration
(Vivaflow 50, cut-off 100.000 Dalton). The washed sus-
pension was then freeze-dried (Criolab 8—Criofarma—
Torino, Italy) in the presence of 2% (p/v) of lactose
(Pharmatose DCL11, DMW international). Average sizes
and polydispersity indices of MT-SLN were measured
by photocorrelation spectroscopy (Zetasizer—3000 HS—
Malvern Instruments, UK). The analysis of percentages
of melatonin incorporated in SLN was performed by a
reversed HPLC method (Jasco pump-2080; Jasco Detector
UV-2080). The mobile phase was water–methanol (50:50).
The analysis was performed at a flow rate of 1 ml/min at
229 nm. A weighed amount of freeze-dried MT-SLN at
first was dissolved in methanol. An aliquot, dissolved in
the mobile phase, was then employed.
2.1.3. Thickened Gel Preparation
To 2 g of a mixture (w/w) water propylene glycol (70:30),
200 mg of MT-SLN (MT = 18%) was kindly mixed
and successively under stirring Carbopol 940® (1.20%)
was added, obtaining a gel. Vertical Franz cells were
used: the full-thickness dorsal skin of male hairless mice
(athymic-nude-Charles River) aged 4–5 weeks was used.
The skin previously rinsed with normal saline was sand-
wiched between the two ground panels. The gel (0.3 g)
was gently applied to the donor site of the skin surface,
which had an available diffusion area of 1.6 cm.2 The con-
tent of the receptor cell was continuously stirred and ther-
mostated at 25. At appropriate intervals the entire contents
of the receptor chamber was removed by HPLC determi-
nation and the cell refilled with fresh aqueous solution at
pH 6.0. The experiments were performed in triplicate.
2.1.4. Transdermal Preparation
Freeze-dried MT-SLN (MT = 2%) were dispersed in a
mixture of water and propylene glycol (70:30)(w/w) and
successively added of Carbopol 940® (1.2%) obtaining a
gel (MT-SLN-TD); the melatonin concentration in the gel
was 1.8 mg/g (w/w).
2.1.5. Oral Preparation
Freeze dried amounts of MT-SLN (MT= 413%) contain-
ing 3 mg MT were included in hard gelatine capsules
(Scherer) for oral administration (MT-SLN-O); 3 mg of
MT was also included in hard-gelatine capsules for oral
administration (MT-S).
2.2. MT Administration and Subjects
The subjects enrolled were healthy volunteers. They gave
informed consent and the experiment was approved by the
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local ethical committee. Inclusion criteria were: absence
of sleep disorders, excessive daytime somnolence or dis-
orders of sleep-wake cycle, absence of known diseases
involving central nervous system or endocrine system,
absence of any medication treatment at least one month
before the study. All subjects maintained a regular sleep-
cycle during the week of the study.
In 7 subjects (4 males, 3 females; mean age: 43.8±9.3
years) one capsule of MT-SLN-O was orally administered
at 8.30 a.m. One capsule of MT-S was administered to
the same subjects after one week at 8.30 a.m. The days
of oral administrations subjects abstained from eating in
the morning in order to prevent possible interferences with
absorption. Blood samples were collected at regular inter-
vals: every 30 minutes until 2nd hour after administration,
every hour until 8th hour, and finally at 24th hour.
In 10 subjects (5 males, 5 females, mean age 48.2±
16.3 years) 2 g of MT-SLN-TD (corresponding to mela-
tonin 3.6 mg, 0.4 mg MT/cm2) was applied at 8.30 a.m. to
9 cm2 skin area over the anterior part of the chest, delimi-
ted by 1 mm thick biocompatible foam tapes and cov-
ered by a polyester-based membrane (3M® Scotchpak®)
and an occlusive membrane (Smith and Nephew® OpSite
Flexigrid®) in order to prevent evaporation of some com-
ponents. In these conditions a single layer of MT-SLN
(1 mm thick) was directly in contact with skin surface and
acted as a reservoir of MT for transdermal absorption. MT-
SLN-TD patch was then removed after 24 hour. The skin
was not pre-treated. In all subjects blood samples were
collected at 8 a.m., half an hour after administration, then
every 2 hours until 11th hour after administration. In two
subjects blood samples were collected at 8 a.m., half an
hour after administration, every 2 hours until 11th hour.
In the following 2 days, the blood samples were collected
every 3–4 hours from 8 a.m. to 7 p.m. on 2nd day and
from 8 a.m. to 3 p.m. on 3rd day. The temporary interrup-
tion of blood collection corresponds to night time and the
sleep period. As baseline controls, in this group of sub-
jects blood samples were collected after one week and at
the same intervals from 8 a.m. until 7 p.m.
2.3. MT Assays in Serum
Blood was centrifuged, immediately separated and stored
at −20 C until assayed. Serum MT levels were determined
after diethyl ether extraction using radioimmunoassay
(RIA) method. All samples from an individual subject were
analyzed in the same kit. The assay sensitive was 2 pg/ml.
Duplicate MT determinations were made from each sam-
ples. The intra-assay coefficients of variation (CV) ranged
from 1 to 5%. The intra-assay CV was 8.1%.
2.4. Pharmacokinetic Analysis
Plasma drug concentration data of the individual subjects
were analyzed by standard noncompartmental methods.
The individual peak concentrations (Cmax) and times to
Cmax (Tmax) were obtained. The area under the curve
(AUC) to the last measurable concentration was calculated
with the log-linear trapezoidal rule, and the absorption
and elimination half-life determined. The data were statis-
tically analysed using Prism 3.0® (GraphPad Software®)
and Sigma Plot for Windows® version 8.0. Two-tailed
unpaired Student’s t test or 2-way ANOVA and Post Hoc
tests were used when appropriate to compare different
administrations of MT. The pharmacokinetic data obtained
in two subjects after MT-SLN-TD administration and fol-
lowed for 3 days were fitted with the function y = span x
(e−K1x− e−K2x).
3. RESULTS
3.1. MTSLN Characterization
Three kind of freeze-dried MT-SLN containing different
amounts of melatonin were prepared and characterized:
(a) MT-SLN: MT = 18% for in vitro experiments
(average diameter: 85 nm, polydispersity index: 0.135);
(b) MT-SLN: MT = 2% for transdermal application
(average diameter: 91 nm, polydispersity index: 0.140);
(c) MT-SLN: MT= 413% for oral route (average diame-
ter: 111 nm, polydispersity index: 0.189)
3.2. In Vitro Release of Melatonin from Gel
A flux of melatonin of 31 ug/h/cm2 through hairless
mice skin was obtained. A pseudo-zero order kinetics was
followed.
3.3. Pharmacokinetic Analysis After Oral
Administration
Pharmacokinetic analysis after MT-S and MT-SLN-O
administration is shown in Table I. Figure 1 shows the
profiles of MT plasma levels after MT-SLN-O administra-
tion compared to MT-S. MT absorption demonstrated to
Table I. Pharmacokinetic analysis after MT-S and MT-SLN-O
administration.
Mean SD Min Max
MT-S
Cmax 8316 4077 4450 10970
Tmax 30 — 30 30
AUC 851484 506426 52891 82600
Half-life of elimination 482 89 383 663
MT-SLN-O
Cmax 8284 3076 4210 10850
Tmax 514 146 30 60
AUC 1699447 649544 52891 82600
Half-life of elimination 931 371 596 1556
∗p = 0009, p = 0018, MT-S versus MT-SLN-O (2-tailed unpaired student’s
t test).
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Fig. 1. MT plasma level profiles after MT-S ( and MT-SLN-O () administration.
be rapid as in all subjects MT plasma levels higher than
200 pg/ml were detected in blood samples after 30 min-
utes from administration of both MT-S and MT-SLN-O.
Mean Cmax after MT-S and MT-SLN-O administration
were comparable and did not show statistical differences
(831.6 ± 407.7 pg/ml vs. 828.4 ± 307.6 pg/ml). Tmax
after MT-SLN-O administration resulted delayed of about
20 minutes compared to MT-S. However, mean half life
of elimination of the drug after MT-SLN-O administra-
tion was significantly higher compared to MT-S (93.1±
37.1 min vs. 48.2 ± 8.9 min; p = 0009) and, more
interestingly, mean AUC after MT-SLN-O administration
was considerably higher compared to MT-S (169944.7±
64954.4 pg/ml × hour vs. 85148.4± 50642.6 pg/ml ×
hour; p = 0018). MT plasma level above 50 pg/ml was
found in 5 subjects and 2 subjects, respectively 6 hours
and 8 hours after MT-SLN-O administration. On the con-
trary only one subject presented MT plasma level above
50 pg/ml, 5 hours after MT-S administration, and none
after 7 hours. No relationship between age or sex and MT
plasma levels could be evidenced using both formulations.
Mild somnolence was referred by 3 subjects after 3.2 ±
1.2 hours from MT-SLN-O administration and lasted for
a maximum of 2 hours. No subjects presented significant
side effects.
3.4. Pharmacokinetic Analysis After Transdermal
Administration
Figure 2 shows mean MT plasma level profiles at base-
line and after MT-SLN-TD administration including all
the subjects. Table II and Figure 3 shows pharmacokinetic
analysis and MT plasma level profile after MT-SLN-TD
Fig. 2. MT plasma level profile at baseline and after MT-SLN-TD
administration (10 subjects).
Fig. 3. MT plasma levels and fit function y = span∗ (e−K1x − e−K2x)
after MT-SLN-TD administration (2 subjects: CD and SG).
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Table II. Pharmacokinetic analysis after MT-SLN-TD administration
(2 subjects: CD and SG). Fit function: y= span∗ (e−K1x−e−K2x) + base-
line (mean of control values). Cmax and AUC do not include baseline.
CD SG
SPAN 1475 5364
K1 003731 004326
K2 0138 006913
Half life of absorption (hour) 1857411 1601942
Half life of elimination (hour) 5021739 1002459
AUC (pg/ml × hour) 2884523 4640151
Tmax (hour) 1299029 1811984
Cmax (pg/ml) 6628431 9166227
administration, together with the fit of function y = span∗
(e−K1x − e−K2x), considering only the two subjects who
underwent blood sample collection until 54th hour. MT
absorption demonstrated to be slow. A significant increase
of MT plasma level was detected 4.5 hours after patch
application and Cmax was lower than peak plasma levels
obtained after MT-SLN-O administration. On the contrary
Tmax and half life of elimination resulted much longer
than oral administration, with K2 (elimination) higher than
K1 (absorption). Clearly nocturnal endogenous MT plasma
concentration overlies exogenous MT during nighttime and
early morning, but after 9 a.m. and during daytime the
contribution of endogenous MT is lower than 20 pg/ml.
So, mean MT plasma level at 8 a.m. and 9 a.m. resulted
higher compared to MT plasma levels detected 2.5 hours
after administration, but this difference was not statisti-
cally significant according to post-hoc tests. As shown in
Figures 2 and 3 mean MT plasma levels resulted signif-
icantly higher compared to baseline and above 50 pg/ml
from 4.5 hours until at least 24 hours after MT-SLN-TD
administration. No adverse effect was referred apart from
a mild transient erythema on the site of patch application.
4. DISCUSSION
The pseudozero order kinetics of melatonin included in
SLN and released through hairless mice skin aimed us to
study the in vivo release in healthy subjects. Significant
absorption and detectable plasma level of MT was found
in all subjects after oral and transdermal administration.
These data suggest that also in vivo a significant release
of drugs from SLN may be achieved. Indeed only 0.4 mg
of melatonin in SLN/cm2 was able to perform interesting
amounts of MT for more then 24 hours.
Compared to standard oral formulation, MT-SLN-O
administration demonstrated to obtain comparable peak
plasma levels of the drug, even if delayed of about half
an hour. More interestingly, detectable and clinically sig-
nificant MT plasma levels after MT-SLN-O administration
were maintained for a longer period of time. This means
that this new formulation is able to give a sustained release
of the drug that could be useful for those substances
devoid of favourable kinetics such as MT. In previous
studies1415 the targeting to lymph of SLN, both drug-
loaded or unloaded, was proved after duodenal administra-
tion in laboratory animals. Probably, also if the capsules
containing SLN were not gastro-resistant, MT-SLN may
partly be targeted to lymph allowing longer half life of
the molecule in vivo. In fact MT half-life of elimination
is about 40 min after an intravenous bolus and when it is
administered orally low bioavailability and rapid clearance
from plasma is seen, primarily due to a marked first pass
hepatic metabolism.89 In our study mean half life of elim-
ination is about doubled compared to these data regarding
intravenous administration and compared to standard for-
mulation we used as control.
Nevertheless some differences among subjects were
found and deserve further investigation in order to analyse
all the variables involved in oral absorption in vivo. In our
study high MT plasma levels were detected in all subjects
after about one hour, and MT plasma level above 50 pg/ml
after 8 hours was found in 2 subjects after MT-SLN-O
administration. This means that MT absorption is rela-
tively rapid initially, and present little difference among
subjects. On the contrary subjects may differ according to
the capacity of SLN to work as a reservoir for the drug, or
they may differ according to the rapidity of drug clearance
from plasma. Our preliminary data are in accordance with
the coexistence of both these hypotheses. Only one subject
presented prolonged relatively high MT levels both after
MT-S and MT-SLN-O administration, so a low clearance
from plasma may be hypothesized. In all other subjects
this relation was not found, so different amount of drug
released over time by SLN may explain our data.
More interesting, pharmacokinetic analysis regarding
MT-SLN-TD administration demonstrates that plasma
level of the drug comparable to oral administration may
be achieved for more than 24 hours. These data are very
encouraging, and represent a new model of a transdermal
sustained release of drugs devoid of favourable pharma-
cokinetics. Transdermal drug delivery systems offer sev-
eral advantages over the parental and oral routes as they
may avoid the patient’s unwillingness or incapability to
swallow oral preparations and may prevent issues associ-
ated with hepatic first-pass metabolism, poor absorption
from the gastrointestinal tract and variable bioavailability.
In recent years technologies for the development of
transdermal drug delivery systems have shown great
progresses and now more molecules for therapeutic use
can be included in media for transdermal absorption.2021
Our model is based on new pharmaceutical technology
that uses SLN as a reservoir and a carrier of the drug.
The long half life of absorption makes this formulation
not suitable for drugs requiring a rapid increase of plasma
levels. On the contrary this preparation might be able to
give sustained release of the drugs for several h, accord-
ing to the amount of the drug included in SLN and the
application areas.
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We have chosen to include melatonin into SLN because
of its low incidence of adverse effects even at high
dosages.7 Moreover the components of SLN are biocom-
patible. In our study tolerability of MT-SLN-TD and MT-
SLN-O was good and no adverse effect occurred apart
from predictable mild somnolence and transient erythema
after gel application. This means that, at least at dosages
used in our study, SLN administration via oral and trans-
dermal route is safe. Further studies in a larger group
of subjects and after prolonged treatments are needed in
order to verify tolerability and long-term possible adverse
effects. Nevertheless our study indicates that MT-SLN-O
and MT-SLN-TD may be considered models for new sus-
tained delivery systems in vivo that could be generali-
zed to other substances, in particular to those medications
requiring prolonged high plasma levels despite their unfa-
vourable pharmacokinetics. As dosages and concentrations
of drugs included in SLN can be varied, different plasma
level profile could be obtained, so disclosing new possi-
bilities for sustained delivery systems. Further studied will
be directed to optimize dosages and concentration of the
drugs included in SLN, and to verify the adequate applica-
tion areas over the skin for transdermal delivery systems.
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